NCT04829604 2026-03-09
ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
Ambrx, Inc.
Phase 2 Active not recruiting
Clinical Trials
6 trialsNCT06014658 2026-03-02
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
MBrace Therapeutics
Phase 1/2 Recruiting
NCT03255070 2024-02-01
A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)
Ambrx, Inc.
Phase 1 Completed
NCT01605318 2024-01-24
Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer
Gilead Sciences
Phase 1/2 Terminated
NCT03489525 2022-03-28
MEDI2228
MedImmune LLC
Phase 1 Completed
NCT01915472 2021-08-19
A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer
Gilead Sciences
Phase 2 Withdrawn